Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Morphosys Ag ADR (NQ: MOR )

18.96 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Morphosys Ag ADR

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma
PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal... 
From MorphoSys AG
Via AccessWire
Exposures COVID-19 Product Safety
Earnings Scheduled For May 5, 2021
Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT... 
Via Benzinga
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma
From Incyte
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Snowflake (NYSE:SNOW... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Monday morning saw 78 companies set new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Rocket Companies (NYSE:RKT).... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Conformis (NASDAQ:CFMS) stock moved upwards by 29.53% to $1.09 during Monday's pre-market session. The company's market cap stands at $198.8 million. As... 
Via Benzinga
MorphoSys AG (MOR) Q1 2021 Earnings Call Transcript
MOR earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
MorphoSys AG Reports First Quarter 2021 Results
- MonjuviU.S. net product sales of € 12.9 million (US$ 15.5 million) - Tremfya royalties of € 11.6 million - Reaffirming group revenue guidance of € 150 to € 200 million - Conference call and webcast... 
From MorphoSys AG
Via AccessWire
Exposures COVID-19
Stocks That Hit 52-Week Lows On Wednesday
Wednesday morning, 15 companies reached new 52-week lows. Interesting Facts: The largest company in terms of market cap to set a new 52-week low was Vistra (NYSE:... 
Via Benzinga
DGAP-News: Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021
Conference Call Alert Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021 MUNICH, GERMANY / ACCESSWIRE / April 28, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ: MOR), a... 
From MorphoSys AG
Via AccessWire
Exposures COVID-19
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,... 
Via Benzinga
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / April 19, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced the first... 
From MorphoSys AG
Via AccessWire
Exposures COVID-19 Product Safety
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
From Incyte and MorphoSys AG
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.